Literature DB >> 7840591

Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.

S K Spangler1, M R Jacobs, P C Appelbaum.   

Abstract

Agar dilution was used to compare the in vitro activity of CP 99,219 with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. CP 99,219 yielded a MIC for 50% of the strains tested (MIC50) of 0.25 micrograms/ml and a MIC90 of 1.0 microgram/ml, with 99.6% of the strains susceptible at a breakpoint of 2.0 micrograms/ml. Ciprofloxacin and grepafloxacin were less active (MIC50, 4.0 micrograms/ml; MIC90, 32.0 micrograms/ml and 2.0 and 16.0 micrograms/ml, respectively). Metronidazole was active against all gram-negative rods (MIC90, 4.0 micrograms/ml), but 31% of the gram-positive anaerobes were resistant at > 8.0 micrograms/ml. Cefoxitin was active against 84% of all strains at < or = 16.0 micrograms/ml, with a MIC50 of 4.0 micrograms/ml and a MIC90 of 32.0 micrograms/ml. Tazobactam enhanced the activity of piperacillin against > 95% of the beta-lactamase-producing gram-negative anaerobic rods (MIC90, 16.0 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7840591      PMCID: PMC284766          DOI: 10.1128/AAC.38.10.2471

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance.

Authors:  P C Appelbaum; A Philippon; M R Jacobs; S K Spangler; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

3.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

4.  In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.

Authors:  B B Gooding; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

5.  In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

6.  Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.

Authors:  A L Barry; P C Fuchs; D M Citron; S D Allen; H M Wexler
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

7.  Characterization of a beta-lactamase from Clostridium clostridioforme.

Authors:  P C Appelbaum; S K Spangler; G A Pankuch; A Philippon; M R Jacobs; R Shiman; E J Goldstein; D M Citron
Journal:  J Antimicrob Chemother       Date:  1994-01       Impact factor: 5.790

8.  Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.

Authors:  A Bauernfeind
Journal:  J Antimicrob Chemother       Date:  1993-04       Impact factor: 5.790

10.  Evaluation of two methods for rapid testing for beta-lactamase production in Bacteroides and Fusobacterium.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

View more
  37 in total

1.  Comparative antianaerobic activity of BMS 284756.

Authors:  D B Hoellman; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.

Authors:  Mihaela Peric; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  Control of Clostridium difficile-associated diarrhea by antibiotic stewardship in a small community hospital.

Authors:  Alice Schabas; David N Fisman; Richard Schabas
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

4.  Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.

Authors:  M L Peterson; L B Hovde; D H Wright; G H Brown; A D Hoang; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  J P Bédos; V Rieux; J Bauchet; M Muffat-Joly; C Carbon; E Azoulay-Dupuis
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  Quality control limits for dilution and disk diffusion susceptibility tests of trovafloxacin against eight quality control strains.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

7.  In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates.

Authors:  L Verbist; J Verhaegen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

8.  In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin.

Authors:  P C Fuchs; A L Barry; S D Brown; D L Sewell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

9.  Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2009-04-07       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.